Support making the FDA Rare Pediatric Disease Priority Review Voucher Program permanent.

Kat Cammack · Florida · Republican

policy impact 0.58 specificity 0.90 extraction confidence 94%

Commitment kind: action. Promised action: Join a bipartisan effort to make the Rare Pediatric Disease Priority Review Voucher Program permanent.. Promised outcome: Permanent authorization of the Rare Pediatric Disease Priority Review Voucher Program.. Deadline: unknown; not assumed expired. As U.S. Representative for Florida's 3rd District, Cammack was quoted in a September 14, 2026 congressional press release about bipartisan legislation to permanently authorize the FDA Rare Pediatric Disease Priority Review Voucher Program.

Occurrences

“ Every child deserves a chance at life, no matter how rare their disease ,” said Congresswoman Kat Cammack. “ A rare diagnosis should never mean that a child is left behind in the search for a treatment or cure. The Rare Pediatric Disease Priority Review Voucher Program encourages America’s innovators to take on these devastating diseases and pursue breakthroughs that can give children and their families hope. I’m proud to join this bipartisan effort to make this important program permanent.”

Cammack said she was joining a bipartisan effort to make the Rare Pediatric Disease Priority Review Voucher Program permanent.

Bilirakis, Barragán, Cammack, Auchincloss, Kean & Mullin Introduce Bipartisan Bill to Permanently Protect Rare Pediatric Disease Drug Development Program -Legislation Provides Long-Term Certainty to Encourage Investment in Lifesaving Treatments for Childr | Congressman Gus Bilirakis
primary · press_release · model gpt-5.5

Action Mr. Bilirakis (for himself, Ms. Barragán, Mrs. Cammack, Mr. Auchincloss, Mr. Kean, and Mr. Mullin) introduced the following bill; which was referred to the Committee on Energy and Commerce Bill Number H.R. 10359 Bill Version Introduced in House (IH) Short Title Priority for Pediatric Cures Act Full Title To amend the Federal Food, Drug, and Cosmetic Act to permanently extend the authority of the Secretary of Health and Human Services to award priority review vouchers for rare pediatric disease products.

Cammack was listed as a cosponsor of H.R. 10359, a bill to permanently extend HHS authority to award rare pediatric disease priority review vouchers.

H.R. 10359 (IH) - Priority for Pediatric Cures Act - BILLS-119hr10359ih | Content Details | GovInfo
primary · other · model gpt-5.5

Evidence

verified · Source version 66622 · locator 1260

Mr. Bilirakis (for himself, Ms. Barragán, Mrs. Cammack, Mr. Auchincloss, Mr. Kean, and Mr. Mullin) introduced the following bill; which was referred to the Committee on Energy and Commerce

Fetched verbatim passage. AI summary (separate from source): Within the lookback window, Cammack was listed as an original participant/cosponsor on H.R. 10359, a bill referred to committee rather than enacted.

unresolved same_term A for effort

H.R. 10359 (IH) - Priority for Pediatric Cures Act - BILLS-119hr10359ih | Content Details | GovInfo
primary · model gpt-5.5 · confidence 94%

verified · Source version 66635 · locator 1276

Section 529(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)) is amended by striking paragraph (5).

Fetched verbatim passage. AI summary (separate from source): The introduced bill text would remove the statutory termination paragraph for rare pediatric disease PRVs, matching the permanent-authorization goal, but it remains only an introduced bill.

unresolved same_term A for effort

H.R. 10359 Introduced in House - Priority for Pediatric Cures Act
secondary · model gpt-5.5 · confidence 92%

unverified · Source version 66637 · locator unknown

Section 529(b)(5) of the FD&C Act provides that after September 30, 2029, FDA may not award any rare pediatric disease priority review vouchers.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): A recent FDA Federal Register notice confirms that, under current law in the lookback window, the program still has a 2029 sunset and has not been made permanent.

partial same_term

Federal Register :: Fee Rate for Using a Priority Review Voucher in Fiscal Year 2027
secondary · model gpt-5.5 · confidence 93%

unverified · Source version 66639 · locator unknown

As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): FDA’s current program page shows a temporary extension through September 30, 2029, not permanent authorization.

partial same_term

Rare Pediatric Disease Designation and Priority Review Voucher Programs
secondary · model gpt-5.5 · confidence 91%

unverified · Source version 66641 · locator unknown

Cammack | Republican | FL | Nay

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Cammack voted against H.R. 7148 on House passage; that appropriations vehicle later carried the temporary PRV reauthorization, but this omnibus vote is not direct evidence of opposition to permanent authorization.

unresolved same_term

Office of the Clerk, U.S. House of Representatives
secondary · model gpt-5.5 · confidence 75%

Assessments

Public state: delivered As of 2026-09-23 · verified · . Original AI recommendation (not independently established): delivered. same_term A for effort

The verified commitment was to support or join the bipartisan effort to make the Rare Pediatric Disease Priority Review Voucher Program permanent, not a promise that permanent authorization would be enacted. Verified GovInfo evidence shows Cammack was included among members introducing H.R. 10359, and verified bill text shows the bill would remove the termination provision for rare pediatric disease priority review vouchers. That materially fulfills the support/join-effort commitment in the same term, though it does not prove enactment of permanent authorization.

provider codex_cli · model gpt-5.5 · confidence 94%